Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 To 2011

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2190-2196

  Shih, Ya Chen Tina ^a   Smieliauskas, Fabrice ^b   Geynisman, Daniel M ^c   Kelly, Ronan J ^d   Smith, Thomas J ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG COST; DRUG DECOMPOSITION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; TREATMENT DURATION; ECONOMICS; HEALTH CARE COST; HEALTH INSURANCE; MIDDLE AGED; NEOPLASMS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; NEOPLASMS; UNITED STATES;

EID: 84937135127     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.2320     Document Type: Article

References (35)

1. American Society of Clinical Oncology: The state of cancer care in America, 2014: A report by the American Society of Clinical Oncology. J Oncol Pract 10:119-142, 2014
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
3. Shih YC, Ganz PA, Aberle D, et al: Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 31:4151-4157, 2013
4. Kelly RJ, Smith TJ: Delivering maximum clinical benefit at an affordable price: Engaging stakeholders in cancer care. Lancet Oncol 15:e112-e118, 2014
5. Aggarwal S: Targeted cancer therapies. Nat Rev Drug Discov 9:427-428, 2010
6. Sledge GW Jr: What is targeted therapy? J Clin Oncol 23:1614-1615, 2005
7. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
8. EMD Serono: EMD Serono Specialty Digest (ed 10). Rockland, MA, EMD Serono, 2014
9. National Cancer Institute: Targeted cancer therapies. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted
10. Raborn ML, Pelletier EM, Smith DB, et al: Patient out-of-pocket payments for oral oncolytics: Results from a 2009 US claims data analysis. J Oncol Pract 8:9s-15s, 2012 (suppl)
11. Dorn SD, Wei D, Farley JF, et al: Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. Clin Gastroenterol Hepatol 10:278-284, 2012
12. Oaxaca R: Male-female wage differentials in urban labor markets. Int Econ Rev 14:693-709, 1973
13. Magellan Pharmacy Solutions: 2012 Medical Pharmacy and Oncology Trend Report. https://www1.magellanmedicaid.com/resource-center/medical-pharmacy-and-oncology-trend-report.aspx
14. Jacobson M, Earle CC, Price M, et al: How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) 29:1391-1399, 2010
15. Bach PB, Saltz LB, Wittes RE: In cancer care, cost matters. New York Times, October 14, 2012:A25. http://www.nytimes.com/2012/10/15/opinion/a-hospital-saysno-to-an-11000-a-month-cancer-drug.html
16. Neubauer MA, Hoverman JR, Kolodziej M, et al: Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6:12-18, 2010
17. Kreys ED, Koeller JM: Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. J Oncol Pract 9:e241-e247, 2013
18. Barkley R: Key features of the CMMI oncology care model (OCM). http://obroncology.com/obrgreen/article/key-features-of-the-CMMI-Oncology-Care-Model
19. American Society of Clinical Oncology: Potential approaches to sustainable, long-lasting payment reform in oncology. J Oncol Pract 10:254-258, 2014
20. Howard DH, Conti RM: Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013. J Clin Oncol 32:416s, 2014 (suppl 15s; abstr 6525)
21. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
22. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Chronic myelogenous leukemia (version 1.2015) http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf
23. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Acute lymphoblastic leukemia (version 1.2014). http://www.nccn.org/professionals/physician-gls/pdf/all.pdf
24. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Non-small cell lung cancer (version 2.2015). http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
25. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Kidney cancer (version 3.2015). http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf
26. Navarro RP, Stern CS, Haley R: Prescription drug benefits in managed care, in Kongstvedt PR (ed): Essentials of Managed Health Care (ed 6). Burlington, MA, Jones and Bartlett Learning, 2012
27. Pollack A: AbbVie deal heralds changed landscape for hepatitis drugs. http://www.nytimes.com/2014/12/22/business/pharmacy-deal-heralds-changed-landscapefor-hepatitis-drugs.html
28. Maas A: Advanced RCC gains scrutiny as more drugs are approved for it. Specialty Pharmacy News 9, 2012
29. Cavallo J: ASCO develops new strategy to increase value in cancer care. http://www.ascopost.com/issues/may-15,-2014/asco-develops-new-strategy-toincrease-value-in-cancer-care.aspx
30. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
31. Printz C: Drug parity legislation: States, organizations seek to make oral cancer drugs more affordable. Cancer 120:313-314, 2014
32. Patients Equal Access Coalition: Oral chemotherapy access legislative landscape. http://peac.myeloma.org/oral-chemo-access-map/
33. Fendrick AM, Buxbaum J, Westrich K: Supporting consumer access to specialty medications through value-based insurance design. http://www.npcnow.org/vbid14
34. Berndt ER, McGuire T, Newhouse JP: A primer on the economics of prescription pharmaceutical pricing in health insurance markets. http://www.nber.org/papers/w16879
35. Baghdadi R: The Part D premium lesson for exchanges. https://www.pharmamedtechbi.com/publications/rpm-report/first-take/2014/3/blum